Hemophilia B

Common Name(s)

Hemophilia B, Hereditary factor IX deficiency disease, Christmas disease

Hemophilia B is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding or oozing following an injury or surgery. In severe cases of hemophilia, heavy bleeding occurs after minor trauma or even in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms may not become apparent until abnormal bleeding occurs following surgery or a serious injury. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty. Hemophilia B is inherited in an X-linked recessive pattern and is caused by mutations in the F9 gene.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemophilia B" for support, advocacy or research.

Bleeding Disorders Alliance Illinois

The Bleeding Disorders Alliance Illinois exists to improve the quality of life for persons affected by hemophilia and other inherited bleeding disorders.

Last Updated: 25 Sep 2013

View Details
Hemophilia Federation of America

The Hemophilia Federation of America is a national non-profit organization that assists and advocates for the bleeding disorders community.

Last Updated: 6 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemophilia B" for support, advocacy or research.

Bleeding Disorders Alliance Illinois

The Bleeding Disorders Alliance Illinois exists to improve the quality of life for persons affected by hemophilia and other inherited bleeding disorders.

http://www.bdai.org

Last Updated: 25 Sep 2013

View Details
Hemophilia Federation of America

The Hemophilia Federation of America is a national non-profit organization that assists and advocates for the bleeding disorders community.

http://www.hemophiliafed.org

Last Updated: 6 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hemophilia B" returned 163 free, full-text research articles on human participants. First 3 results:

[The skin as a vehicle for gene therapy: hemophilia B, an application model].
 

Author(s): Isaura Araceli González-Ramos, Ana Rebeca Jaloma-Cruz

Journal: Gac Med Mex. ;151(2):266-9.

 

Artificial skin offers important advantages in gene therapy tor its biosafety and simple monitoring. An easy access of keratinocytes through small biopsies and their in vitro expansion enriched with epithelial stem cells, make them an ideal target for long-term therapeutic transgene ...

Last Updated: 7 May 2015

Go To URL
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
 

Author(s): Danko Milošević, Ernest Bilić, Danica Batinić, Mirjana Poropat, Ranka Štern-Padovan, Slobodan Galić, Daniel Turudić

Journal:

 

Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only three cases are reported in children, all of them with hemophilia A.

Last Updated: 21 Feb 2015

Go To URL
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
 

Author(s): Paul E Monahan, Junjiang Sun, Tong Gui, Genlin Hu, William B Hannah, David G Wichlan, Zhijian Wu, Joshua C Grieger, Chengwen Li, Thipparat Suwanmanee, Darrel W Stafford, Carmen J Booth, Jade J Samulski, Tal Kafri, Scott W J McPhee, R Jude Samulski

Journal: Hum. Gene Ther.. 2015 Feb;26(2):69-81.

 

Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand ...

Last Updated: 14 Feb 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hemophilia B" returned 3 free, full-text review articles on human participants. First 3 results:

Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.
 

Author(s): Victor A Ferraris, Leonard I Boral, Alice J Cohen, Susan S Smyth, Gilbert C White

Journal: Cardiol Rev. ;23(2):53-68.

 

With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-normal life expectancies and present with typical age-related cardiovascular conditions. Evidence-based guidelines for medical or surgical management of cardiovascular conditions in individuals ...

Last Updated: 6 Feb 2015

Go To URL
Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.
 

Author(s): Deepak Raj, Andrew M Davidoff, Amit C Nathwani

Journal: Expert Rev Hematol. 2011 Oct;4(5):539-49.

 

Therapies currently used for hemophilia involve injection of protein concentrates that are expensive, invasive and associated with side effects such as development of neutralizing antibodies (inhibitors) that diminish therapeutic efficacy. Gene transfer is an attractive alternative ...

Last Updated: 23 Sep 2011

Go To URL
[Extracorporeal shock wave lithotripsy in a patient with hemophilia B].
 

Author(s): T Yokoyama, Y Nasu

Journal: Nippon Hinyokika Gakkai Zasshi. 1993 Mar;84(3):566-9.

 

We report a successful treatment of extracorporeal shock wave lithotripsy (ESWL) on a renal stone in a patient with severe hemophilia B. The patient was 44 years old man who had suffered left flank colicky pain with gross hematuria. A radiographic study showed a left renal stone, ...

Last Updated: 21 Jul 1993

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Gene Therapy Study for Hemophilia B
 

Status: Recruiting

Condition Summary: Hemophilia B

 

Last Updated: 10 Dec 2015

Go to URL
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
 

Status: Recruiting

Condition Summary: Hemophilia A; Hemophilia B; Von Willebrand's Disease

 

Last Updated: 31 Aug 2015

Go to URL

Last Updated: 13 Oct 2015

Go to URL